Envisagenics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 35

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 17

Envisagenics General Information

Description

Developer of a bioinformatics platform designed to accelerate the development of novel therapeutics. The company's platform incorporates advanced artificial intelligence and machine learning algorithms to analyze, predict, and interpret transcriptomic data, enabling researchers to identify and validate potential drug targets.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 30-02 48th Avenue
  • Suites 140 and 150
  • Long Island City, NY 11101
  • United States
+1 (516)
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Corporate Office
  • 30-02 48th Avenue
  • Suites 140 and 150
  • Long Island City, NY 11101
  • United States
+1 (516)

Envisagenics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Envisagenics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Secondary Transaction - Private 01-Apr-2026 Completed Pre-Clinical Trials
11. Later Stage VC (Series B) 18-Jul-2024 Completed Pre-Clinical Trials
10. Debt - General 17-May-2023 Completed Pre-Clinical Trials
9. Grant 02-Aug-2022 Completed Pre-Clinical Trials
8. Later Stage VC (Series A) 24-Sep-2021 Completed Pre-Clinical Trials
7. Debt - PPP 01-May-2020 Completed Pre-Clinical Trials
6. Accelerator/Incubator Completed Pre-Clinical Trials
5. Grant 12-Sep-2019 Completed Pre-Clinical Trials
4. Grant 05-Apr-2018 $1.62M $2.45M Completed Pre-Clinical Trials
3. Seed Round 30-Nov-2017 $2.35M $2.45M Completed Pre-Clinical Trials
To view Envisagenics’s complete valuation and funding history, request access »

Envisagenics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-2
Series B-1
Series A-4
Series A-3
Series A-2 6,964,570 $0.000100 $0.03 $0.43 $0.43 1x $0.43 14.06%
Series A-1 277,760 $0.000100 $0.01 $0.25 $0.25 1x $0.25 0.56%
To view Envisagenics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Envisagenics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a bioinformatics platform designed to accelerate the development of novel therapeutics. The company's platf
Discovery Tools (Healthcare)
Long Island City, NY
35 As of 2026

Toronto, Canada
 

Chesterfield, MO
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Envisagenics Competitors (11)

One of Envisagenics’s 11 competitors is Deep Genomics, a Venture Capital-Backed company based in Toronto, Canada.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Deep Genomics Venture Capital-Backed Toronto, Canada
Partek Corporate Backed or Acquired Chesterfield, MO
Standard BioTools Formerly VC-backed Boston, MA
Caris Life Sciences Formerly PE-Backed Irving, TX
Strand (Biotechnology) Formerly VC-backed Bangalore, India
You’re viewing 5 of 11 competitors. Get the full list »

Envisagenics Patents

Envisagenics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4205121-A2 Neoantigens, methods and detection of use thereof Pending 28-Aug-2020
EP-4205121-A4 Neoantigens, methods and detection of use thereof Pending 28-Aug-2020
US-20230263872-A1 Neoantigens, methods and detection of use thereof Pending 28-Aug-2020
WO-2022047242-A2 Neoantigens, methods and detection of use thereof Inactive 28-Aug-2020
WO-2022047242-A3 Neoantigens, methods and detection of use thereof Inactive 28-Aug-2020 A61P35/00
To view Envisagenics’s complete patent history, request access »

Envisagenics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Envisagenics Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bristol-Myers Squibb Corporation Minority
Myeloma Investment Fund Not-For-Profit Venture Capital Minority
National Institutes of Health Government
Angel (individual) Minority
Hawktail Venture Capital Minority
You’re viewing 5 of 17 investors. Get the full list »

Envisagenics FAQs

  • When was Envisagenics founded?

    Envisagenics was founded in 2014.

  • Where is Envisagenics headquartered?

    Envisagenics is headquartered in Long Island City, NY.

  • What is the size of Envisagenics?

    Envisagenics has 35 total employees.

  • What industry is Envisagenics in?

    Envisagenics’s primary industry is Discovery Tools (Healthcare).

  • Is Envisagenics a private or public company?

    Envisagenics is a Private company.

  • What is Envisagenics’s current revenue?

    The current revenue for Envisagenics is .

  • How much funding has Envisagenics raised over time?

    Envisagenics has raised $40.5M.

  • Who are Envisagenics’s investors?

    Bristol-Myers Squibb, Myeloma Investment Fund, National Institutes of Health, , and Hawktail are 5 of 17 investors who have invested in Envisagenics.

  • Who are Envisagenics’s competitors?

    Deep Genomics, Partek, Standard BioTools, Caris Life Sciences, and Strand (Biotechnology) are some of the 11 competitors of Envisagenics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process